According to the 2021 Chinese Society of Clinical Oncology (CSCO) guidelines on prostate cancer, adjuvant ADT following an RP is recommended for patients with localized and locally advanced prostate cancer, especially for those patients with persistently elevated serum PSA levels (≥ 0.2 ng/mL) or lymph node metastasis after an RP7. This evidence concerns the gene KLK3 and prostate cancer.